Abstract
Ph1-positive chronic myelocytic leukemia (CML) developing in a treated case of acute promyelocytic leukemia (APL) is reported. The patient was a 62-year-old male who was diagnosed as having APL in December 1978. He was treated with daunorubicin, Ara-C and 6MP and a complete remission was obtained 4 months later. But APL recurred in February 1981. He was treated with BHAC, aclarubicin, 6MP and prednisolone. He remained in continuous complete remission for 5 years, when all therapy was discontinued. After then, the leukocytes count continued to rise and a diagnosis of Ph1-positive CML was made in September 1986. His leukocytes count has been well controlled with the use of busulfan. The event in this case suggests a possibility of the Ph1-positive CML being a secondary disease related to prior long term chemotherapy.
MeSH terms
-
Aclarubicin / administration & dosage
-
Aclarubicin / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Cytarabine / analogs & derivatives
-
Daunorubicin / administration & dosage
-
Daunorubicin / adverse effects
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Leukemia, Promyelocytic, Acute / pathology
-
Male
-
Mercaptopurine / administration & dosage
-
Mercaptopurine / adverse effects
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Prednisolone / administration & dosage
-
Prednisolone / adverse effects
-
Remission Induction
Substances
-
Cytarabine
-
Aclarubicin
-
Prednisolone
-
Mercaptopurine
-
Methotrexate
-
Daunorubicin